

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 June 2001 (14.06.2001)

PCT

(10) International Publication Number
WO 01/42238 A1

- (51) International Patent Classification⁷: **C07D 401/04, A61K 31/47**
- (21) International Application Number: **PCT/EP00/12335**
- (22) International Filing Date: **7 December 2000 (07.12.2000)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
9929037.1 **8 December 1999 (08.12.1999)** **GB**
- (71) Applicant (*for all designated States except US*): **GLAXO WELLCOME S.P.A.** [IT/IT]; Via Alessandro Fleming, 2, I-37135 Verona (IT).
- (72) Inventor; and
- (75) Inventor/Applicant (*for US only*): **ORLANDI, Alessandra** [IT/IT]; Glaxo Wellcome S.p.A., Via Alessandro Fleming, 2, I-37135 Verona (IT).
- (74) Agent: **FILLER, Wendy, Anne**; Glaxo Wellcome PLC, Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 ONN (GB).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**
- *With international search report.*
 - *Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: **HETEROCYCLIC DERIVATIVES**

(57) Abstract: The present invention relates to a novel salt of enantiomer A of 7-chloro-4-(2-oxo-1-phenyl-3-pyrrolidinylidene)-1,2,3,4-tetrahydro-2-quinoline carboxylic acid or a solvate thereof, to processes for its preparation, to pharmaceutical compositions containing it and to its use in therapy and in particularly its use as medicine for antagonising the effects of excitatory amino acids upon the NMDA receptor complex.


WO 01/42238 A1

Heterocyclic Derivatives

The present invention relates to a novel salt of enantiomer A of 7-chloro-4-(2-oxo-1-phenyl-3-pyrrolidinylidene)-1,2,3,4-tetrahydro-2-quinoline

5 carboxylic acid or a solvate thereof, to processes for its preparation, to pharmaceutical compositions containing it and to its use in therapy and in particularly its use as medicine for antagonising the effects of excitatory amino acids upon the NMDA receptor complex.

10 The compound 7-chloro-4-(2-oxo-1-phenyl-3-pyrrolidinylidene)-1,2,3,4-tetrahydro-2-quinolinecarboxylic acid of formula (I) is inter alia described in WO 99/64411 which also refers to physiologically acceptable salts thereof and more particularly it describes an enantiomer of the compound of formula (I), which is referred to therein as enantiomer A and a sodium salt thereof.



20 The enantiomer A of 7-chloro-4-(2-oxo-1-phenyl-3-pyrrolidinylidene)-1,2,3,4-tetrahydro-2-quinolinecarboxylic acid is a particularly potent antagonist of the NMDA receptor complex, and for its use in medicine there exists a need for the compound to be prepared in a form suitable for ease of isolation in a large scale manufacture and for ease of formulating into an

25 acceptable product for administration to patients. These requirements are not conveniently met by either enantiomer A or sodium salt thereof.

It has been found that the meglumine salt of enantiomer A can readily be prepared and isolated suitable in a pure form by a process that is suitable for use on a large scale, and the said salt can be conveniently obtained with the required high degree of purity and good stability and thus fulfils the exacting criteria required in the preparation of pharmaceutical compositions for administration to patients.

The present invention thus provides the meglumine salt of enantiomer A of 7-chloro-4-(2-oxo-1-phenyl-3-pyrrolidinylidene)-1,2,3,4-tetrahydro-2-quinolinecarboxylic acid of formula (I) or a solvate (e.g. hydrate) thereof (hereinafter referred to as the compound of the invention).

Particularly the invention provides the meglumine salt of enantiomer A of 7-chloro-4-(2-oxo-1-phenyl-3-pyrrolidinylidene)-1,2,3,4-tetrahydro-2-quinolinecarboxylic acid in a crystalline form.

More particularly, according to one embodiment, the invention provides for a hydrate crystalline form of the the meglumine salt of enantiomer A of 7-chloro-4-(2-oxo-1-phenyl-3-pyrrolidinylidene)-1,2,3,4-tetrahydro-2-quinolinecarboxylic acid (hereinafter referred to as form 1), characterised by the following X-ray powder diffraction pattern expressed as 2 Theta (θ) value

Angle 2 θ

4.356	18.641	22.993
11.263	18.725	23.681
11.659	20.546	25.043
12.757	21.362	25.598
12.877	22.234	26.823
13.962	22.379	28.753
15.482	22.801	
17.242	22.921	

According to a further embodiment of the invention there is provided for another crystalline form of the meglumine salt of enantiomer A of 7-chloro-4-(2-oxo-1-phenyl-3-pyrrolidinylidene)-1,2,3,4-tetrahydro-2-

5 quinolinecarboxylic acid (hereinafter referred to as form 2) characterised by the following X-ray powder diffraction pattern expressed as 2 Theta (θ) value

Angle 2 θ

5.480	19.553	25.225
8.233	20.505	25.802
10.942	21.939	26.484
15.299	22.787	27.524
16.424	23.154	27.865
16.658	23.381	28.547
19.116	24.194	38.345

10 The compound of the invention can be obtained in more than one crystalline form. It is to be understood that the invention includes all such forms or mixture thereof.

The compound of the invention is an excitatory amino acid antagonist. More particularly it is a potent antagonist at the strychnine insensitive
15 glycine binding site associated with the NMDA receptor complex. As such it is a potent antagonist of the NMDA receptor complex. This compound is therefore useful in the treatment or prevention of neurotoxic damage or neurodegenerative diseases. Thus the compound is useful for the
20 treatment of neurotoxic injury which follows cerebral stroke, thromboembolic stroke, hemorrhagic stroke, cerebral ischemia, cerebral vasospasm, hypoglycemia, amnesia, hypoxia, anoxia, perinatal asphyxia cardiac arrest. The compound of the invention is useful in the treatment of chronic neurodegenerative diseases such as: Huntingdon's disease, Alzheimer's senile dementia, amyotrophic lateral sclerosis, Glutaric
25 Acidaemia type, multi-infarct dementia, status epilepticus, contusive injuries (e.g. spinal cord injury and head injury), viral infection induced

neurodegeneration (e.g. AIDS, encephalopathies), Down syndrome, ocular neurodegeneration (e.g. glaucoma), epilepsy, schizophrenia, depression, migraine, headaches including cluster headaches and or tension headaches, anxiety, pain (e.g. inflammatory pain and neuropathic pain),
5 neurogenic bladder, irritable bowel syndrome and or visceral hyperalgesia, emesis, irritative bladder disturbances, drug dependency, including withdrawal symptoms from alcohol, cocaine, opiates, nicotine (e.g. smoking cessation) benzodiazepines and. inhibition of tolerance induced by opioids (i.e. morphine).

10 The potent and selective action of the compound of the invention at the strychnine-insensitive glycine binding site present on the NMDA receptor complex may be readily determined using conventional test procedures. Thus the ability to bind at the strychnine insensitive glycine binding site was
15 determined using the procedure of Kishimoto H *et al.*, J Neurochem 1981, 37, 1015-1024. The selectivity of the action of compounds of the invention for the strychnine insensitive glycine site was confirmed in studies at other ionotropic known excitatory amino acid receptors. Thus the compound of the invention was found to show little or no affinity for the kainic acid
20 (kainate) receptor, α -amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptor or at the NMDA binding site.

25 The compound of the invention may be found to inhibit NMDA induced convulsions in mice using the procedure Chiamulera C *et al.*, Psychopharmacology (1990), 102, 551-552.

30 The neuroprotective activity of the compound of the invention may be demonstrated in the middle cerebral artery occlusion preparation in mice, using the procedure described by Chiamulera C. *et al.*, European Journal of Pharmacology, 216 (1992) pp. 335-336.

The ability of compound of the invention to alleviate withdrawal symptoms from nicotine following smoking cessation may be demonstrated in

conventional tests of nicotine induced relapse using the procedure described in C. Chiamulera *et al.*, Arch. Pharmacol., 358, 1998.

5 The ability of the compound of the invention to inhibit pain may be demonstrated in conventional analgesic screen such as those described by Dubuisson and Dennis, *Pain*, 1977, 4:161-174; J.J. Bennett and J.K Xue, *Pain*, 1988, 41, 87-107.

10 The invention also provides for the use of the compound of the invention for use in therapy and in particular use as medicine for antagonising the effects of excitatory amino acids upon the NMDA receptor complex.

15 The invention also provides for the use of the compound of the invention for the manufacture of a medicament for antagonising the effects of excitatory amino acids upon the NMDA receptor complex.

20 According to a further aspect, the invention also provides for a method for antagonising the effects of excitatory amino acids upon the NMDA receptor complex, comprising administering to a patient in need thereof an antagonistic amount of the compound of the invention.

25 It will be appreciated by those skilled in the art that reference herein to treatment extends to prophylactics as well as the treatment of established diseases or symptoms.

30 It will further be appreciated that the amount of the compound of the invention required for use in treatment will vary with the nature of the condition being treated, the route of administration and the age and the condition of the patient and will be ultimately at the discretion of the attendant physician. In general however doses employed for adult human treatment will typically be in the range of 2 to 800mg per day, dependent upon the route of administration.

Thus for parenteral administration a daily dose will typically be in the range 20-100mg, preferably 60-80mg per day. For oral administration a daily dose will typically be within the range 200-800mg, e.g. 400-600mg per day.

- 5 The desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example as two, three, four or more sub-doses per day.

- 10 While it is possible that, for use in therapy, a compound of the invention may be administered as the raw chemical, it is preferable to present the active ingredient as a pharmaceutical formulation.

- 15 The invention thus further provides a pharmaceutical formulation comprising the compound of the invention together with one or more pharmaceutically acceptable carriers thereof and, optionally, other therapeutic and/or prophylactic ingredients. The carrier(s) must be 'acceptable' in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

- 20 The compositions of the invention include those in a form especially formulated for oral, buccal, parenteral, inhalation or insufflation, implant or rectal administration.

- 25 Tablets and capsules for oral administration may contain conventional excipients such as binding agents, for example, syrup, acacia, gelatin, sorbitol, tragacanth, mucilage of starch or polyvinylpyrrolidone; fillers, for example, lactose, sugar, microcrystalline cellulose, maize-starch, calcium phosphate or sorbitol; lubricants, for example, magnesium stearate, stearic acid, talc, polyethylene glycol or silica; disintegrants, for example, potato starch or sodium starch glycollate, or wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well known in the art. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions emulsions, syrups or elixirs, or may be presented as a dry product for constitution with water or other suitable
- 30

vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example, sorbitol syrup, methyl cellulose, glucose/sugar syrup, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible
5 fats; emulsifying agents, for example, lecithin, sorbitan mono-oleate or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters, propylene glycol or ethyl alcohol; solubilizers such as surfactants for example polysorbates or other agents such as cyclodextrins; and preservatives, for example, methyl or
10 propyl p- hydroxybenzoates or ascorbic acid. The compositions may also be formulated as suppositories, e.g. containing conventional suppository bases such as cocoa butter or other glycerides.

For buccal administration the composition may take the form of tablets or
15 lozenges formulated in conventional manner.

The composition according to the invention may be formulated for parenteral administration by injection or continuous infusion. Formulations for injection may be presented in unit dose form in ampoules, or in multi-
20 dose containers with an added preservative. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. Alternatively the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile,
25 pyrogen-free water, before use.

For administration by inhalation the compounds according to the invention are conveniently delivered in the form of an aerosol spray presentation from pressurised packs, with the use of a suitable propellant, such as
30 dichlorodifluoromethane, trichlorofluoromethane, dichloro-tetrafluoroethane, carbon dioxide or other suitable propellants, such as dichlorodifluoromethane, trichlorofluoromethane, dichloro-tetrafluoroethane, carbon dioxide or other suitable gases, or from a nebuliser. In the case of a

pressurised aerosol the dosage unit may be determined by providing a valve to deliver a metered amount.

5 Alternatively, for administration by inhalation or insufflation, the compounds according to the invention may take the form of a dry powder composition, for example a powder mix of the compound and a suitable carrier such as lactose or starch. The powder composition may be presented in unit dosage form in, for example, capsules or cartridges of e.g. gelatin, or blister
10 packs from which the powder may be administered with the aid of an inhaler or insufflator.

The composition according to the invention may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by
15 intramuscular injection. Thus for example, the compounds of the invention may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

20 The compositions according to the invention may contain between 0.1 - 99% of the active ingredient, conveniently from 30- 95% for tablets and capsules and 3-50% for liquid preparations.

25 A further aspect of the invention provides a process for the preparation of the compound of the invention.

Thus in one embodiment compound of the invention may be prepared by treating a solution of the enantiomer A (I) with meglumine in a suitable solvent such as aprotic solvent (i.e. acetone, tetrahydrofuran) or alkanol
30 such as ethanol.

The invention further provides a method for producing the compound of the invention in a crystalline form.

Thus the compound of the invention in hydrate crystalline form (form 1) may be prepared by treating a solution of enantiomer A of 7-chloro-4-(2-oxo-1-phenyl-3-pyrrolidinylidene)-1,2,3,4-tetrahydro-2-quinolinecarboxylic acid in ethanol with meglumine dissolved in water .

5 The reaction is carried out at room temperature and in an environment free of the compound of the invention in crystalline form 2.

The crystalline form 2 may obtained by crystallisation of the compound of the invention from a mixture of water and a water miscible organic
10 antisolvent.

Suitable water miscible organic antisolvents for use in the crystallisation include alkanol (e.g. ethanol, IMS (ethanol/methanol 95/5) or isopropanol), acetone or acetonitrile.

A particularly convenient water miscible organic antisolvent is ethanol or
15 acetone.

Conveniently the crystallisation process is carried out by adding the antisolvent to a solution of the compound of the invention dissolved in
20 water.


In a further embodiment of the process, the crystalline form 2 may be obtained by crystallisation of the compound of the invention from a mixture of suitable organic solvents.

Thus, form 2 may be obtained by dissolution of the compound of the
25 invention in a suitable organic solvent (i.e. N,N-dimethylformamide or 1-methyl-2-pyrrolidone) followed by treatment with a suitable organic antisolvent such as alkanol (e.g. ethanol, IMS (ethanol/methanol 95/5) or isopropanol) or an aprotic solvent (e.g. acetone, tetrahydrofuran dichloromethane, ethylacetate, toluene, or acetonitrile).

30 The process is preferably carried out at a temperature ranging between 20-45°C.

The enantiomer A of the compound of formula (I) may be prepared according to the processes described in WO 99/64411 which is incorporated by reference.

In a preferred embodiment, the enantiomer A of the compound of formula (I) may be prepared by stereoselective enzymatic hydrolysis of compounds of formula (II) with ferulic acid esterase in a pure form.



wherein R is a carboxyl protecting group.

Suitable carboxyl protecting group R for use in this reaction includes C₁₋₄ alkyl such as methyl, ethyl, propyl, butyl or arylmethyl groups such as benzyl, nitrobenzyl or trityl.

The reaction is conveniently carried out in an aprotic solvent such as DMSO, tetrahydrofuran in the presence of a suitable aqueous buffer (i.e. citrate, phosphate buffer or CaCl₂). If required, a solubilising agent such as Tween-80 may be added to the reaction mixture.

In a further process the enzyme may be immobilized and the reaction is carried out in essentially "neat" water-saturated organic solvents such as methyl *tert*-butyl ether or *tert*-amyl alcohol.

The stereoselective enzymatic hydrolysis of compounds of formula (II) with ferulic acid esterase in a pure form is novel and represents a further aspect of the invention.

The invention also extends to the meglumine salt of enantiomer A of 7-chloro-4-(2-oxo-1-phenyl-3-pyrrolidinylidene)-1,2,3,4-tetrahydro-2-quinolinecarboxylic acid of formula (I) or a solvate thereof when prepared from the enantiomer A of formula (I) which has been obtained by stereoselective enzymatic hydrolysis of compounds of formula (II) with ferulic acid esterase in a pure form.

Meglumine is commercially available (Aldrich).

In the Intermediates and Example unless otherwise stated:
Melting points (m.p.) were determined on a Gallenkamp m.p. apparatus and are uncorrected. All temperatures refer to °C. Proton Magnetic Resonance (¹H-NMR) spectra were recorded at 500 MHz, chemical shifts are reported in ppm downfield (δ) from Me₄Si, used as internal standard, and are assigned as singlets (s), doublets (d), doublets of doublets (dd), triplets (t), quartets (q) or multiplets (m). Column chromatography was carried out over silica gel (Merck AG Darmstadt, Germany). DBU = 1,8-diazobicyclo [5,4,0]undec-7-ene.

The X-ray powder diffraction pattern of a crystalline form of the compound of the invention was obtained by loading the sample into the diffractometer (Siemens D5005 X-ray diffractometer equipped with θ/θ goniometer, scintillation counter and graphite monochromator. The diffractometer was set up with the instrumental parameters given below:

Instrumental parameters

MONOCHROMATIC RADIATION: Cu - 1.54056/1.54439
2θ RANGE: 2°-40° 2θ
GENERATOR VOLTAGE/CURRENT: 40kV/50mA
STEP SIZE: 0.02° 2θ
TIME PER STEP: 2 sec⁻¹
ROTATION: on
DIVERGENCE/ANTISCATTERING SLIT: variable
SAMPLE HOLDER: round cavity on low-background plate.
The spectrum obtained was analysed using the data evaluation software EVA3.0.

Enantiomer A refers to a single enantiomer whose absolute stereochemistry was not determined

Intermediate 1

5 (±)-Ethyl 2-(5-chloro-2-iodoanilino)-4-pentenoate

To a solution of 2-iodo 4 chloro aniline (9.1g) in dry toluene (150 ml) ethyl glyoxylate (50% solution in toluene, 14.6 ml) and MgSO₄ (2 g) were added and the resulting suspension was refluxed overnight. It was then filtered and concentrated to dryness under high vacuum at 50°C for 1.5 h. The
10 resulting brown oil was dissolved in dichloromethane (150 ml) cooled to -78°C and TiCl₄ (99.995% purity, 4 ml) was added via syringe. The suspension was stirred 15 min at -78°C, then allowed to warm to rt over 15 min before being cooled again to -78°C. Allyltributyltin (17 ml) was then added and the reaction allowed to proceed for 1 h. The black solution was
15 poured into 200 ml of ethyl acetate and washed first with a saturated solution of NH₄Cl (2 x 150 ml), then with water and brine. The organic phase was dried and concentrated to give the crude product, which was purified by column chromatography (cyclohexane, then cyclohexane/ethyl acetate 98/2) to give the title compound (10.4 g) as a colourless oil.
20 NMR (CDCl₃) δ (ppm) 7.57 (d, 1H), 6.49 (dd, 1H), 6.45 (dd, 1H), 5.79 (m, 1H), 5.25 (dd, 1H) 5.24 (dd, 1H), 4.83 (d, 1H), 4.25 (q, 2H), 4.13 (m, 1H), 2.66 (m, 2H), 1.30 (t, 3H)

Intermediate 2

25 (±)-Ethyl 2-(5-chloro-2-iodoanilino)-4-oxobutanoate

A solution of intermediate 1 (5.2g) in dichloromethane (150 ml) was cooled to -78°C and ozone was bubbled through it until the clear solution became brick-red. At this point the flux of ozone was interrupted and the solution was purged with nitrogen for a few minutes. Triphenyl phosphine (7.1g) was
30 added and stirring continued for 1.5 h, without control of the temperature. The resulting solution was poured into 200 ml of ethyl acetate and washed first with a saturated solution of NH₄Cl (2 x 150 ml), then with water and

brine. The organic phase was dried and concentrated to give the crude product, which was purified by column chromatography (cyclohexane/ethyl acetate 80/20) to give the title compound (2.4g) as a colourless oil.

5 ¹NMR (DMSO) δ (ppm) 9.80 (t, 1H), 7.57 (d, 1H), 6.55 (d, 1H), 6.51 (dd, 1H), 4.99 (d, 1H), 4.46 (m, 1H), 4.24 (q, 2H), 3.08 (m, 2H), 1.28 (t, 3H)

Intermediate 3

(±) E-Ethyl 2-(5-chloro-2-iodoanilino)-4-(2-oxo-1-phenyl-3-pyrrolidinylidene) butanoate (4a); (±)-Z-Ethyl 2-(5-chloro-2-iodoanilino)-4-(2-oxo-1-phenyl-3-pyrrolidinylidene) butanoate(4b)

10 To a solution of intermediate 2 (2.4g) in acetonitrile (100 ml) at r.t. intermediate 3(3.7 g) and DBU (13 ml) were added and stirring was continued overnight at -20°C. The crude solution was poured into 200 ml of ethyl acetate and washed with a saturated solution of NH₄Cl (2 x 150 ml),
15 then with water and brine. The organic phase was dried and concentrated to give the crude product as a 4/1 mixture of 4a/4b compounds. Purification by column chromatography (cyclohexane/ethyl acetate 80/20) gave the title 4a (2.16 g) and the 4b (0.5g) compounds as colourless oils.

Intermediate 3a

20 ¹NMR (CDCl₃) δ (ppm) 7.72 (d, 2H), 7.56 (d, 1H), 7.38 (t, 2H), 7.16 (t, 1H), 6.6 (m, 1H), 6.50 (dd, 1H), 6.49 (d, 1H), 4.88 (d, 1H), 4.26 (m, 3H), 3.87 (t, 2H), 2.79 (m, 4H), 1.30 (t, 3H)

Intermediate 3b

25 ¹NMR (CDCl₃) δ (ppm) 7.69 (d, 2H), 7.52 (d, 1H), 7.38 (t, 2H), 7.17 (t, 1H), 6.47 (d, 1H), 6.44 (dd, 1H), 5.98 (m, 1H), 5.00 (d, 1H), 4.22 (m, 2H), 4.13 (m, 1H), 3.84 (t, 2H), 3.2-3.6 (m, 2H), 2.85 (m, 2H), 1.26 (t, 3H)

Intermediate 4

30 (±)-Ethyl 7-chloro-4-(2-oxo-1-phenyl-3-pyrrolidinylidene)-1,2,3,4-tetrahydro-2-quinolinecarboxylate

To a solution of intermediate 3b (370g) in toluene (5.2lit), Triethylamine (248ml), Triphenylphosphine (7.4g) and PdCl₂ (2.52g) were added. The resulting solution was warmed to 100 °C and stirred for 2h. The suspension was chilled to 20-25 °C and toluene (2.6ml) was added.

The reaction mixture was washed with NH₄Cl 8% (3x5.2lit) and water (5.2lit). The organic layer was filtered over a celite pad and it was washed with toluene (1lit); then it was distilled under vacuum (T=50°C; P=60mbar) to reach 6.3lit. After cooling to T=20-25°C, isooctane (5.2lit) was dropped over 30 min. The precipitate was stirred for 2h 30min then it was filtered and washed with a mixture toluene/isooctane 1/1 (1.85lit). The yellow solid was dried in vacuum at T= 40°C for 18h to obtain the title compound as a yellow solid (210g).

m.p. 160-162°C

¹NMR (DMSO): 7.72 (m, 2H); 7.39 (m, 2H); 7.20 (d, 2H); 7.15 (m, 2H); 6.96 (dd, 1H); 6.74 (d, 1H); 6.57 (dd, 1H); 4.29 (dd, 1H); 4.21 (m, 1H); 4.02 (m, 1H); 3.93 (m, 1H); 3.82 (m, 1H); 3.69 (m, 1H); 3.20 (m, 1H). 2.92 (m, 2H); 2.92 (m, 2H); 0.93 (t, 3H).

Example 1

(-)-Meglumine salt of enantiomer A of 7-chloro-4-(2-oxo-1-phenyl-3-pyrrolidinylidene)-1,2,3,4-tetrahydro-2-quinolinecarboxylic acid (form 2)

Method A

16.5g of Lipase Amano AP12 (*Aspergillus niger* lipase) were suspended in 360ml of 0.1M citrate buffer (pH=3) in a stirred vessel at 15°C.

27.5g of intermediate 4 were dissolved in 190ml of dimethyl sulfoxide at 20°C and this solution added into the vessel under vigorous stirring.

The mixture was stirred at 37°C for 24hrs and 27.5g of filter aid (Dicalite) were added to the reaction mixture which was then cooled to 20°C. After addition of 275ml of aq. 0.2M hydrochloric acid the mixture was cooled to +6°C and then filtered.

The filter cake was washed with 140ml of aq. 0.2M hydrochloric acid and 140ml of water before being dried.

The so obtained dried filter cake (55g) was extracted at 20°C with 660ml of acetone, then filtered off washing with 220ml of acetone. To the filtrate, 33ml of an aqueous solution of meglumine (0.2g/ml) were added. The so obtained suspension was digested and the solid filtered and washed with

275ml of acetone. After drying the crude title compound was obtained as a yellow solid (16.2g).

4g of this crude compound were then dissolved in 10ml of water by heating at 50°C, then 110ml of EtOH were added. After digestion at 20°C the solid was filtered and dried to obtain the purified title compound as a yellow solid (3.75g), m.p. 186°C.

The title compound (5mg) was dissolved in 1ml of a mixture D₂O/DMSO 95/5.

¹H-NMR (D₂O/DMSO 95/5) δ (ppm) 7.44 (2H, d), 7.37 (2H, t), 7.19 (1H, t), 7.16 (1H, d), 6.66 (1H, d), 6.58 (1H, dd), 3.96 (1H, m), 3.78-3.50 (8H, m), 3.46 (1H, dd), 3.99 (1H, dd), 3.10 (1H, dd), 3.05 (1H, d), 3.02 (2H, m), 2.64 (3H, s).

[α]_D = -321.7; λ = 598 nm; 20°C conc mg/ml 0.12% solvent = methanol.

Method B

To a warmed at 35° C 0.1M Sodium citrate buffer obtained by mixing a 0.1M aqueous solution (412ml) of citric acid and a 0.1M aqueous solution (196ml) of trisodic citrate dihydrate into a jacketed reactor, an aqueous solution (Conc = 40mg/ml) of the enzyme ferulic acid esterase (19.6ml) and dimethyl sulfoxide (98ml) were added. To the resulting solution, a solution of Intermediate 4 (49g) in dimethyl sulfoxide (270ml) was added. Then the mixture was stirred at 37-38°C for 24hrs.

After cooling at 20°C the reaction mixture was extracted twice with 2-butanone (1470 mL) and the organic layer was washed with a 6% sodium chloride aqueous solution (2x980ml) and a 25% sodium chloride aqueous solution (392ml) then, after addition of further 2-butanone (490ml) the solvent was distilled off at atmospheric pressure to a residual 200ml volume. Then acetone (1323ml) was added to the mixture and a 20% aqueous meglumine solution (60ml) was dropped into the mixture. The resulting suspension was stirred for 1h, then filtered, washed with acetone (490ml) and dried at 40°C under vacuum for ca 16hrs to obtain the crude title compound as a yellow solid (26.9 g).

26.8g of the crude title compound was dissolved with water (107,2ml) at 55°C and after filtration cooled at 45°C. Then acetone (268ml) was dropped under stirring and the mixture seeded with the title compound. Acetone

(402ml) was then further added and the resulting slurry was stirred at 20°C for 1hr and at 2°C for 2hrs and then solid was filtered washed with acetone (134ml) and dried under vacuum at 40°C for ca 16hrs to obtain the title compound (23g), m.p. 185-187°C.

5

Table 1

The X-ray powder diffraction pattern of the product of Example 1 in terms of 'd' spacings is as follows

Angle (°2θ)	d value (Å)
5.480	16.114
8.233	10.731
10.942	8.079
15.299	5.787
16.424	5.393
16.658	5.317
19.116	4.639
19.553	4.536
20.505	4.328
21.939	4.048
22.787	3.899
23.154	3.838
23.381	3.801
24.194	3.676
25.225	3.528
25.802	3.450
26.484	3.363
27.524	3.238
27.865	3.199
28.547	3.124
38.345	2.346

10

Example 2

(-)-Meglumine salt of enantiomer A of 7-chloro-4-(2-oxo-1-phenyl-3-pyrrolidinylidene)-1,2,3,4-tetrahydro-2-quinolinecarboxylic acid (form 1)

(-)-Sodium 7-chloro-4-(2-oxo-1-phenyl-3-pyrrolidinylidene)-1,2,3,4-tetrahydro-2-quinolinecarboxylate(2.5g) was suspended in ethyl acetate (75ml) and extracted with aqueous HCl 1.5N (25ml). The organic layer was evaporated to dryness to obtain 7-chloro-4-(2-oxo-1-phenyl-3-pyrrolidinylidene)-1,2,3,4-tetrahydro-2-quinoline -2-carboxylic acid as a white foam (2.3g) which was dissolved in ethanol (69ml) at 23°C under nitrogen and then a solution of meglumine (1.25g) in water (5.3) was added in 20 minutes. The suspension was stirred at 23°C under nitrogen for 24 hours. The solid was filtered and dried at 40°C for 20 hours (3.0g), m.p. 112°C.

¹H-NMR (D₂O/DMSO 95/5) δ (ppm) 7.73 (2H, d), 7.38 (2H, t), 7.15 (1H, d), 7.13 (1H, t), 6.77 (1H, d), 6.45 (1H, dd), 6.40 (1H, bs), 4.10 (1H, bm), 3.79 (3H, m), 3.64 (1H, dd), 3.60 (1H, bm), 3.55 (1H, dd), 3.47 (1H, m), 3.40 (1H, d), 3.38 (1H, t), 3.16 (1H, m), 2.98 (1H, m), 2.85 (1H, m), 2.78 (1H, m), 2.70 (1H, bm), 2.42 (3H, s).

X ray powder diffraction data are reported in Table 2.

Table 2

The X-ray powder diffraction pattern of the product of Example 2 in terms of 'd' spacings is as follows

Angle (°2θ)	d value (Å)
4.356	20.270
11.263	7.849
11.659	7.584
12.757	6.934
12.877	6.869
13.962	6.337
15.482	5.719
17.242	5.139
18.641	4.756

18.725	4.735
20.546	4.319
21.362	4.156
22.234	3.995
22.379	3.969
22.801	3.897
22.921	3.877
22.993	3.865
23.681	3.754
25.043	3.553
25.598	3.477
26.823	3.321
28.753	3.102

Pharmacy Examples

A. Capsules/ Tablets

Active ingredient	20.0mg
Starch 1500	32.5mg
Microcrystalline	200.0mg
Cellulose	
Croscarmellose Sodium	6.0mg
Magnesium Stearate	1.5mg

- 5 The active ingredient is blended with the other excipients. The blend can be used to fill gelatin capsules or compressed to form tablets using appropriate punches. The tablets can be coated using conventional techniques and coatings.

10 B. Tablets

Active ingredient	20.0mg
Sorbitol	200.0mg
Microcrystalline	70.0mg

Cellulose	
Povidone	25.0mg
Croscarmellose	6.0mg
Sodium	
Magnesium Stearate	1.5mg

5 The active ingredient is blended with lactose, microcrystalline cellulose and part of the croscarmellose sodium. The blend is granulated with povidone after dispersing in a suitable solvent (i.e. water). The granule, after drying and comminution is blended with the remaining excipients. The blend can be compressed using appropriate punches and the tablets coated using conventional techniques and coatings.

10 C. Bolus

Active ingredient	0.1-32mg/ml
Trometamol	1.0-5.0mg/ml
water for injection qs to	1ml

15 The formulation may be packed in glass ampoules or vials and syringes with a rubber stopper and a plastic/metal overseal (vials only).

D. Infusion

Active ingredient	0.01-3.2mg/ml
Trometamol	0.2-1.0mg/ml
20 5% dextrose injection qs to	100ml

The formulation may be packed in glass vials or plastic bags.

25 No untoward effects have been observed when compound of the invention has been administered to mice at the pharmacological active doses.

Claims

- 5 1. The meglumine salt of enantiomer A of 7-chloro-4-(2-oxo-1-phenyl-3-pyrrolidinylidene)-1,2,3,4-tetrahydro-2-quinolinecarboxylic acid.
2. A crystalline form of the compound as claimed in Claim 1.
3. The crystalline form described in Example 1.
- 10 4. A process for the preparation of the compound claimed in any of the claims 1 to 3 which comprises mixing enantiomer A of 7-chloro-4-(2-oxo-1-phenyl-3-pyrrolidinylidene)-1,2,3,4-tetrahydro-2-quinolinecarboxylic acid with meglumine in a suitable solvent.
- 15 5. A process for the preparation of a crystalline form as claimed in claim 2 or 3 which comprises crystallising the meglumine salt from a mixture of water and a water miscible organic solvent or from a mixture of suitable organic solvents..
- 20 6. A pharmaceutical composition comprising a compound as claimed in any of claims 1 to 3 in admixture with one or more physiologically acceptable carriers or excipients.
- 25 7. Use of a compound as claimed in any claims from 1 to 3 as medicine for antagonising the effects of excitatory amino acids upon the NMDA receptor complex.
- 30 8. A method of treatment of a mammal including man for conditions where antagonising the effects of excitatory amino acids on the NMDA receptor complex is of therapeutic benefit, comprising administration of an effective amount of a compound as claimed in any of claims 1 to 3.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 00/12335

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D401/04 A61K31/47

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, EPO-Internal, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 99 64411 A (FABIO ROMANO DI ;GLAXO WELLCOME SPA (IT)) 16 December 1999 (1999-12-16) cited in the application claim 1; example 27 ----	1-8
A	WO 98 07704 A (SABBATINI FABIO MARIA ;FABIO ROMANO DI (IT); GLAXO WELLCOME SPA (I) 26 February 1998 (1998-02-26) claim 1 ----	1-8
A	US 5 977 136 A (BERTANI BARBARA ET AL) 2 November 1999 (1999-11-02) claim 1 ----	1-8
A	EP 0 672 662 A (LILLY CO ELI) 20 September 1995 (1995-09-20) page 17, line 10 -page 17, line 13 -----	1-8

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

27 March 2001

Date of mailing of the international search report

09 April 2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Samsam Bakhtiary, M

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 00/12335

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 8
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claim 8 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.1

Claims Nos.: 8

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by surgery

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/12335

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9964411	A	16-12-1999	AU 4509299	A	30-12-1999
			BR 9911145	A	06-03-2001
WO 9807704	A	26-02-1998	AP 877	A	27-09-2000
			AU 724473	B	21-09-2000
			AU 4551897	A	06-03-1998
			BR 9711311	A	17-08-1999
			CN 1227544	A	01-09-1999
			CZ 9900529	A	14-07-1999
			EP 0922034	A	16-06-1999
			NO 990723	A	14-04-1999
			PL 331562	A	19-07-1999
			TR 9900336	T	21-04-1999
			ZA 9707326	A	15-02-1999
US 5977136	A	02-11-1999	AP 876	A	27-09-2000
			AU 708148	B	29-07-1999
			AU 7214896	A	28-04-1997
			BR 9610733	A	13-07-1999
			EP 0854867	A	29-07-1998
			JP 11512728	T	02-11-1999
			NO 981396	A	27-05-1998
			NZ 319596	A	29-09-1999
			CA 2232509	A	10-04-1997
			CN 1202887	A	23-12-1998
			CZ 9800940	A	15-07-1998
			WO 9712870	A	10-04-1997
			HU 9900040	A	28-04-1999
			PL 325966	A	17-08-1998
			TR 9800531	T	22-06-1998
EP 0672662	A	20-09-1995	US 5529999	A	25-06-1996
			CA 2143514	A	05-09-1995
			JP 7267936	A	17-10-1995